Alterity Therapeutics (ATHE) Receivables - Accured (2009 - 2025)

Alterity Therapeutics (ATHE) has reported Receivables - Accured for 17 consecutive years, with $4.8 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Accured rose 20.38% year-over-year to $4.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.8 million (up 20.38% YoY) and the FY2025 annual result came in at $2.8 million, down 2.57% from the prior year.
• Receivables - Accured grew to $4.8 million in Q4 2025 per ATHE's latest filing, from $2.8 million in the prior quarter.
• Over the last five years, Receivables - Accured for ATHE reached as high as $5.0 million in Q4 2022 and fell as low as $40416.8 in Q2 2024.
• A 5-year average of $3.2 million and a median of $3.7 million in 2022 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2021 — Receivables - Accured jumped 6875.88% — and 2023, when it tumbled 97.4%.
• Year by year, Receivables - Accured stood at $4.4 million in 2021, then rose by 13.05% to $5.0 million in 2022, then slipped by 15.45% to $4.2 million in 2023, then retreated by 5.02% to $4.0 million in 2024, then rose by 20.38% to $4.8 million in 2025.
• According to Business Quant data, Receivables - Accured over the past three periods registered $4.8 million, $2.8 million, and $4.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.